This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gerresheimer Records Strong Revenue Growth In The 2012 Financial Year

DÜSSELDORF, Germany, February 14, 2013 /PRNewswire/ --
  • Revenues rise by 11.4% (9.8% at constant exchange rates) to EUR 1,219m
  • Adjusted operating margin (adjusted EBITDA margin) amounts to 19.4%
  • Net income grows by 22.2% to EUR 66.5m
  • Proposed dividend of EUR 0.65 per share
  • Presence in the emerging markets most recently expanded through two acquisitions in India

Gerresheimer AG, one of the leading worldwide partners of the pharma and healthcare industry, has closed the 2012 financial year with significant growth in revenues and profits. "We achieved all our targets in 2012. We recorded another year of strong growth in our business activities with the pharmaceutical sector, which once again proved to be relatively immune to cyclical effects. We are investing heavily in expanding our production capacity for medical devices such as prefilled glass syringes, insulin pens and inhalers. We are also focusing on the fast-growing emerging markets, especially in China, Brazil and India. In 2012 we succeeded in expanding our position in India in particular with the acquisition of two companies there," says Uwe Röhrhoff, CEO of Gerresheimer AG.

In the 2012 financial year ( December 1, 2011 to November 30, 2012), Gerresheimer recorded substantial growth in revenues of 11.4%. Revenues rose to EUR 1,219.1m. At constant exchange rates, revenues increased by 9.8%. In particular Gerresheimer achieved strong growth in the pharma segment coupled with good revenue results in the cosmetic glass business and the life science research segment.

Gerresheimer increased its operating result (adjusted EBITDA) by 8.8% to EUR 236.5m in the 2012 financial year. The adjusted EBITDA margin amounts to 19.4%, compared to the prior year's 19.9%. Net income rose by 22.2% to EUR 66.5m. Earnings per share rose by 19.3% to EUR 1.92. Adjusted earnings per share increased by 4.9% to EUR 2.56.

Gerresheimer invested EUR 118.9m in the 2012 financial year (up from EUR 86.2m in 2011). The company is expanding its production capacity for so-called medical devices, i.e. products for drug delivery such as prefilled glass syringes, insulin pens and asthma inhalers, in Germany, Czech Republic and elsewhere. The Company is also focusing on growth in the emerging markets. In April 2012 Gerresheimer acquired Neutral Glass, one of India's leading manufacturers of pharmaceutical vials. This was followed in December 2012 by the acquisition of the Indian company Triveni, the regional market leader for plastic pharmaceutical packaging and closures. Gerresheimer intends to achieve both organic growth and growth through acquisitions in the future.

Outlook

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs